- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05310929
Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients and Methods The study was conducted in the intensive care unit (ICU) of the Obstetrics and Gynaecology Hospital of Ain-Shams University as a randomized, double-blind, and placebo-controlled study on patients diagnosed with severe PE from July 2016 to June 2018. The study was approved by Ethical Research Committee at Ain Shams University (ethical number FMASU R 47/2019) and all participants provided written informed consent.
Woman eligible for this study were aged between 18-40 years old at greater than 34 weeks of gestation having severe PE without severe features (without imminence of eclampsia or clinical manifestations of target organ damage, as per the ACOG criteria) (7). Severe PE was diagnosed by severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg, repeated measurement should be taken for confirmation no more than 15 minutes later), presence of clinically significant proteinuria (0.3 grams or more of protein in 24-hour urine collection, or urinary protein/creatinine ratio of 30 or more)[8].
Exclusion criteria were patients with chronic hypertension, imminence of eclampsia, target organ damage, active asthma and congestive heart failure. Patients with any known allergy to one of the study drugs are also excluded.
Two hundred patients with severe PE were admitted prepartum to the ICU to stabilize blood pressure. They were randomly assigned to one of two groups (100 in each group): Group N received nitroglycerine intravenous infusion in a concentration of 1 mg/ml, thus 1µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient. Group L received labetalol intravenous infusion in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication was 5 ml/hr. The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes. On any abrupt reduction in blood pressure below 120 mmHg for SBP or 80 mmHg for DBP, the infusion was immediately discontinued, and a bolus of 150 ml lactate ringer was given.
Randomization was attained by using orderly numbered, opaque sealed envelopes containing computer-generated random allocations.
Patients received full intensive care treatment for PE according to the standard protocol of the obstetric ICU of Ain-Shams University. All treatments were provided by physicians who were not involved in the study including infusion of lactated Ringer solution at a starting rate of 75 ml/hr and then adjusted according to the fluid balance, magnesium sulfate (4 gm IV loading dose over a period of 10 minutes and 1 gm/hr IV infusion until 24 hours after delivery as seizure prophylaxis, its dose was adjusted according to renal function) in addition to antihypertensive medications according to the assigned group. The study solution was stopped if maternal pulse reached less than 60 bpm or increased more than 110 bpm.
Vital signs were monitored at admission and until patients were discharged from the ICU using ECG, pulse oximetry, continuous invasive arterial blood pressure monitoring through radial artery, and an indwelling catheter for urine output assessment.
Assessment of fetal well-being was done before starting of the study in the form of cardiotocography (CTG), modified biophysical profile, doppler US on umbilical artery, and growth scan. In addition, continuous fetal heart rate monitoring was done by CTG during the study time.
Severe persistent hypertension was considered when SBP was greater than 160 mmHg or DBP was greater than 110 mmHg after the administration of maximum dose of allocated drug treatment; 20 ml/hr. Hence, patient was shifted to sodium nitroprusside infusion after 2 hours of starting treatment with assigned drugs.
After stabilization of the patient and once the target BP was achieved, induction of labor was started using 3 mg prostaglandin E2 (PGE2) vaginal tablet. It was to be repeated after 6 hours if needed. In case oxytocin was to be used, it was administered at least 6 hours apart from PGE2 last dose.
If the patient was not eligible for induction of labor as in case of previous cesarean delivery (CS), transverse lie of the fetus and other standard obstetrical indications, CS was done at once. CS was also performed in case of failed induction of labor (no uterine contractions nor cervical changes after 6mg of PGE2), fetal compromise, arrest of progress of labor, arrest of cervical dilatation, arrest of fetal descent, and in case of moderate or severe accidental hemorrhage.
The following data were recorded and included demographic characteristics, the time taken to control blood pressure (time from starting infusion till reaching study end point), and number of sudden attacks of hypotension (BP values below the desired level). In addition, side effects of drugs such as tachycardia (HR>100 bpm), bradycardia HR<60 bpm) headache, nausea/vomiting, hypotension, flushing, dizziness were recorded. The mode of delivery either vaginal or caesarean section was also recorded. Fetal outcome regarding stillbirths (death in utero at or after 20 weeks' gestation) and suspected fetal compromise by abnormal CTG (continuous or progressive fetal bradycardia <100 bpm, reduced fetal heart rate variability (<5 bpm) that last more than 90 minutes, atypical variable decelerations with over 50% of contractions, late decelerations for >30 minutes, single prolonged decelerations for more than 3 minutes, or sinusoidal pattern more than 10 minutes). 1 min Apgar score less than 7- and 5-minutes Apgar score less than 7 were also recorded.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- AinShams university hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Woman eligible for this study were aged between 18-40 years old at greater than 34 weeks of gestation having severe PE without severe features (without imminence of eclampsia or clinical manifestations of target organ damage, as per the ACOG criteria) (7). Severe PE was diagnosed by severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg, repeated measurement should be taken for confirmation no more than 15 minutes later), presence of clinically significant proteinuria (0.3 grams or more of protein in 24-hour urine collection, or urinary protein/creatinine ratio of 30 or more) -
Exclusion Criteria:patients with chronic hypertension, imminence of eclampsia, target organ damage, active asthma and congestive heart failure. Patients with any known allergy to one of the study drugs are also excluded.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group N ( nitroglycerine group )
Group N received nitroglycerin intravenous infusion in a concentration of 1 mg/ml, thus 1µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes.
|
for control of blood pressure
Other Names:
|
Experimental: Group L (labetalol group)
. Group L received labetalol intravenous infusion in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr.
The starting infusion rate of the antihypertensive medication was 5 ml/hr.
The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes.
|
for control of blood pressure
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time required to control blood pressure by the assigned group
Time Frame: within 2 hours from start of therapy
|
The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point)
|
within 2 hours from start of therapy
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pregnancy Complications
- Hypertension, Pregnancy-Induced
- Eclampsia
- Pre-Eclampsia
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympathomimetics
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Nitroglycerin
- Labetalol
Other Study ID Numbers
- FMASU R47/2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Pre-eclampsia
-
University of Mississippi Medical CenterCompletedPregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) | Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe) | Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)United States
-
Sohag UniversityRecruitingSevere Pre-eclampsiaEgypt
-
Soroka University Medical CenterUnknown
-
University of WashingtonUniversity of Cape TownCompletedSevere Pre-eclampsia | Mild Pre-eclampsiaSouth Africa, United States
-
Services Institute of Medical Sciences, PakistanUnknownSevere Pre-Eclampsia, AntepartumPakistan
-
Mansoura UniversityCompletedPregnancy | Severe Pre-eclampsiaEgypt
-
Zekai Tahir Burak Women's Health Research and Education...UnknownSevere Preeclampsia | Mild Pre-eclampsiaTurkey
-
Complejo Hospitalario Dr. Arnulfo Arias MadridCompletedSevere Pre-eclampsia With Postnatal ComplicationPanama
-
Mỹ Đức HospitalRecruitingSevere Pre-EclampsiaVietnam
-
Federal Teaching Hospital AbakalikiCompletedEclampsia | Severe Pre-eclampsiaNigeria
Clinical Trials on Labetalol and Glyceril trinitrate
-
Recep Tayyip Erdogan UniversityCompletedCoronary Artery Bypass | Cardiopulmonary BypassTurkey
-
Futura Medical Developments Ltd.CompletedErectile DysfunctionLatvia, Bulgaria, Czechia, Georgia, Hungary, Poland, Russian Federation, Slovakia, Ukraine
-
Cairo UniversityCompletedNon Insertional Achilles TendinopathyEgypt
-
Procris PharmaceuticalsCompletedRaynaud's PhenomenonUnited States
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedPsychotic Disorders | SchizophreniaUnited Kingdom
-
University of California, Los AngelesTerminatedIschemic Stroke | Intracerebral HemorrhageUnited States
-
Futura Medical Developments Ltd.Richmond Pharmacology LimitedCompletedErectile DysfunctionUnited Kingdom
-
Albany Medical CollegeTerminatedPreeclampsia With Severe Features | Chronic Hypertension in Obstetric ContextUnited States
-
Hospital General Universitario ElcheCompletedChronic Anal FissureSpain